Have you been paying attention to the news recently? If you have, you’ll undoubtedly have heard of cannabidiol or CBD. It’s a chemical extracted from the hemp plant, and going by the anecdotal evidence and some research findings, it’s a potent and versatile medicine. Users claim cannabidiol gave them relief from a plethora of conditions, ranging from high blood pressure and chronic pain to anxiety and insomnia.
Last year, the FDA approved a CBD-derived drug to treat seizures caused by two rare and hard to treat pediatric epilepsies, Dravet Syndrome and…
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.